Observation of changes in comprehensive immune pathology in chemotherapy including Nivolumab for patients with refractory malignant pleural mesothelioma
Not Applicable
Recruiting
- Conditions
- Malignant pleural mesothelioma
- Registration Number
- JPRN-UMIN000034312
- Lead Sponsor
- Kawasaki Medical School
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
Initial and resectable malignant pleural mesothelioma
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Nivolumab's efficacy in refractory malignant pleural mesothelioma?
How does Nivolumab-based chemotherapy compare to standard-of-care regimens in mesothelioma outcomes?
Which immune-related biomarkers correlate with response to Nivolumab in malignant pleural mesothelioma?
What are the most common adverse events associated with Nivolumab in mesothelioma treatment?
Are there synergistic combination therapies involving Nivolumab for mesothelioma currently under investigation?